Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.

Press Releases

Press Releases

June 20, 2017 

Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency

April 06, 2017 

Innocrin Pharmaceuticals Appoints Fred Eshelman, PharmD as CEO and is Granted Fast Track Designation by FDA for Seviteronel Treatment of Women with Triple-negative Breast Cancer and Women or Men with Estrogen Receptor-positive Breast Cancer

December 13, 2016 

Innocrin Pharmaceuticals Presents Data from the Ongoing Phase 2 Trial of Seviteronel in Estrogen Receptor-positive or Triple-negative Breast Cancer (CLARITY-01) at the San Antonio Breast Cancer Symposium

October 5, 2016 

Innocrin Pharmaceuticals, Inc. Appoints Edwina Baskin-Bey, MD as Chief Medical Officer and Expands the Ongoing Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer (TNBC)

May 12, 2016 

Innocrin Pharmaceuticals Inc. Begins Phase 2 Breast Cancer Study and Expands 2 Phase 2 Prostate Cancer Studies

January 7, 2016 

Innocrin Pharmaceuticals, Inc. Granted Fast Track Designation by FDA

July 1, 2015

Charles Osborne joins Innocrin Pharmaceuticals as CFO

May 27, 2015 

Innocrin Pharmaceuticals, Inc. Initiates Phase 2 Castration-Resistant Prostate Cancer (CRPC) Study in Men Who Have Failed Enzalutmaide or Abiraterone

April 14, 2015

Innocrin Pharmaceuticals, Inc. Raises $28 Million in Series D Financing

February 26, 2015

Interim Results From Its Phase 1/2 Prostate Cancer Clinical Study and Preclinical Results In A Clinically-Relevant Enzalutamide-Resistant Mouse Model

November 13, 2014

Innocrin Pharmaceuticals and the Prostate Cancer Foundation Join Forces for Innovative Phase 2 Clinical Study

October 22, 2014 

Innocrin Pharmaceuticals Formed: Spin-Out Of Viamet Pharmaceuticals’ Prostate Cancer Program